Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

BACKGROUND AND AIM: Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundgren, Julie R., Færch, Kristine, Witte, Daniel R., Jonsson, Anna E., Pedersen, Oluf, Hansen, Torben, Lauritzen, Torsten, Holst, Jens J., Vistisen, Dorte, Jørgensen, Marit E., Torekov, Signe S., Johansen, Nanna B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778378/
https://www.ncbi.nlm.nih.gov/pubmed/31586493
http://dx.doi.org/10.1186/s12933-019-0937-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778378/
https://www.ncbi.nlm.nih.gov/pubmed/31586493
http://dx.doi.org/10.1186/s12933-019-0937-7

Ejemplares similares